Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry
Background Atopic dermatitis (AD) is frequently associated with asthma and allergic rhinitis (AR). Dupilumab is an effective treatment for pediatric AD, although the effect on atopic comorbidities in pediatric AD patients is limited. Objective To investigate the prevalence of asthma and AR in pediat...
Gespeichert in:
| Veröffentlicht in: | Pediatric allergy and immunology 2024-06, Vol.35 (6), p.e14178-n/a |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 6 |
| container_start_page | e14178 |
| container_title | Pediatric allergy and immunology |
| container_volume | 35 |
| creator | Rijst, Lisa P. van der Groot, Karin M. de Winter‐de Zuithoff, Nicolaas P. A. Bruin‐Weller, Marjolein S. Graaf, Marlies |
| description | Background
Atopic dermatitis (AD) is frequently associated with asthma and allergic rhinitis (AR). Dupilumab is an effective treatment for pediatric AD, although the effect on atopic comorbidities in pediatric AD patients is limited.
Objective
To investigate the prevalence of asthma and AR in pediatric AD patients starting dupilumab treatment and to evaluate the effect of dupilumab on these comorbidities.
Methods
This study included pediatric AD patients (aged 3–17 years) treated with dupilumab between 2019 and 2023. Patients were screened at baseline by a pulmonologist for the presence of asthma and AR. Screening included evaluation of medical history and current symptoms, spirometry (including Forced Expiratory Volume in 1 s (FEV1)), Fractional exhaled Nitric Oxide (FeNO), and measurement of aeroallergen‐specific IgE levels. In patients diagnosed with comorbid asthma and/or AR, measurements were repeated at weeks 16 and 52. Spirometry measurements, FeNO, and aeroallergen‐specific IgE levels during treatment were analyzed using a covariance pattern model.
Results
Eighty‐four patients were included. Asthma was diagnosed in 50 patients (59.5%) and AR in 72 patients (85.7%). Baseline FeNO levels were elevated in both patients with (29.0 ppb (95% CI 22.0–54.0)) and without asthma (26.0 ppb (95% CI 22.0–30.0)). During treatment, FeNO levels decreased (p |
| doi_str_mv | 10.1111/pai.14178 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3070827002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3070827002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2788-4ac4ac88a1fe866d140968afd9da23189002efb6860093c5b8c8817980fb1b823</originalsourceid><addsrcrecordid>eNp10c1q3DAUBWBRWprJpIu-QBF00yycSNaMfdVd_hMINIR0ba7tq0TBtlxJpkzWefBoMpMsChWCu9DHkcRh7KsUBzKtwxHtgVzIEj6wmVRaZ0oo-MhmQotlVshlucN2Q3gUQpaqkJ_ZjgLQugCYseczY6iJ3BneTqPtph5r7gaOIT70yHFoOZJ32HXk72nggYZgo33CaJOyAx-ptRi9bThGN6bRku_TabSBj2nSEMNPfkth6mJYXxMfiB9bd4or7unehuhXe-yTwS7Ql-2cs9_nZ3cnl9n1r4urk6PrrMlLgGyBTdoAKA1BUbRyIdIn0LS6xVxJ0ELkZOoCCiG0apY1JCxLDcLUsoZczdmPTe7o3Z-JQqx6GxrqOhzITaFSohSQlykm0e__0Ec3-SG9bq1yLRalgqT2N6rxLgRPphq97dGvKimqdTVVqqZ6rSbZb9vEqe6pfZdvXSRwuAF_bUer_ydVN0dXm8gXh1WZVA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3072904738</pqid></control><display><type>article</type><title>Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Rijst, Lisa P. van der ; Groot, Karin M. de Winter‐de ; Zuithoff, Nicolaas P. A. ; Bruin‐Weller, Marjolein S. ; Graaf, Marlies</creator><creatorcontrib>Rijst, Lisa P. van der ; Groot, Karin M. de Winter‐de ; Zuithoff, Nicolaas P. A. ; Bruin‐Weller, Marjolein S. ; Graaf, Marlies</creatorcontrib><description>Background
Atopic dermatitis (AD) is frequently associated with asthma and allergic rhinitis (AR). Dupilumab is an effective treatment for pediatric AD, although the effect on atopic comorbidities in pediatric AD patients is limited.
Objective
To investigate the prevalence of asthma and AR in pediatric AD patients starting dupilumab treatment and to evaluate the effect of dupilumab on these comorbidities.
Methods
This study included pediatric AD patients (aged 3–17 years) treated with dupilumab between 2019 and 2023. Patients were screened at baseline by a pulmonologist for the presence of asthma and AR. Screening included evaluation of medical history and current symptoms, spirometry (including Forced Expiratory Volume in 1 s (FEV1)), Fractional exhaled Nitric Oxide (FeNO), and measurement of aeroallergen‐specific IgE levels. In patients diagnosed with comorbid asthma and/or AR, measurements were repeated at weeks 16 and 52. Spirometry measurements, FeNO, and aeroallergen‐specific IgE levels during treatment were analyzed using a covariance pattern model.
Results
Eighty‐four patients were included. Asthma was diagnosed in 50 patients (59.5%) and AR in 72 patients (85.7%). Baseline FeNO levels were elevated in both patients with (29.0 ppb (95% CI 22.0–54.0)) and without asthma (26.0 ppb (95% CI 22.0–30.0)). During treatment, FeNO levels decreased (p < .001) and FEV1 scores increased (p < .001) in patients with asthma. In patients with asthma and/or AR, all aeroallergen‐specific IgE levels decreased between 61.3% and 89.1% at 52 weeks of treatment.
Conclusion
One year of dupilumab treatment, primarily indicated for AD, resulted in a significant improvement in comorbid asthma and a profound decrease in aeroallergen‐specific IgE levels in patients with asthma and/or AR.</description><identifier>ISSN: 0905-6157</identifier><identifier>ISSN: 1399-3038</identifier><identifier>EISSN: 1399-3038</identifier><identifier>DOI: 10.1111/pai.14178</identifier><identifier>PMID: 38899688</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Allergens ; Allergens - immunology ; Allergic rhinitis ; Antibodies, Monoclonal, Humanized - therapeutic use ; Asthma ; Asthma - diagnosis ; Asthma - drug therapy ; Asthma - epidemiology ; Asthma - immunology ; Atopic dermatitis ; atopy ; Child ; Child, Preschool ; children ; Clinical outcomes ; Comorbidity ; Dermatitis ; Dermatitis, Atopic - drug therapy ; Dermatitis, Atopic - immunology ; Dupilumab ; Female ; Humans ; Immunoglobulin E ; Immunoglobulin E - blood ; Immunoglobulin E - immunology ; Male ; Monoclonal antibodies ; Nitric oxide ; Nitric Oxide - metabolism ; Patients ; Pediatrics ; Prevalence ; Registries ; Rhinitis ; Rhinitis, Allergic - drug therapy ; Rhinitis, Allergic - epidemiology ; Rhinitis, Allergic - immunology ; Spirometry ; Treatment Outcome ; type 2 inflammation</subject><ispartof>Pediatric allergy and immunology, 2024-06, Vol.35 (6), p.e14178-n/a</ispartof><rights>2024 The Author(s). published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.</rights><rights>2024 The Author(s). Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2788-4ac4ac88a1fe866d140968afd9da23189002efb6860093c5b8c8817980fb1b823</cites><orcidid>0000-0002-5865-8986</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpai.14178$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpai.14178$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38899688$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rijst, Lisa P. van der</creatorcontrib><creatorcontrib>Groot, Karin M. de Winter‐de</creatorcontrib><creatorcontrib>Zuithoff, Nicolaas P. A.</creatorcontrib><creatorcontrib>Bruin‐Weller, Marjolein S.</creatorcontrib><creatorcontrib>Graaf, Marlies</creatorcontrib><title>Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry</title><title>Pediatric allergy and immunology</title><addtitle>Pediatr Allergy Immunol</addtitle><description>Background
Atopic dermatitis (AD) is frequently associated with asthma and allergic rhinitis (AR). Dupilumab is an effective treatment for pediatric AD, although the effect on atopic comorbidities in pediatric AD patients is limited.
Objective
To investigate the prevalence of asthma and AR in pediatric AD patients starting dupilumab treatment and to evaluate the effect of dupilumab on these comorbidities.
Methods
This study included pediatric AD patients (aged 3–17 years) treated with dupilumab between 2019 and 2023. Patients were screened at baseline by a pulmonologist for the presence of asthma and AR. Screening included evaluation of medical history and current symptoms, spirometry (including Forced Expiratory Volume in 1 s (FEV1)), Fractional exhaled Nitric Oxide (FeNO), and measurement of aeroallergen‐specific IgE levels. In patients diagnosed with comorbid asthma and/or AR, measurements were repeated at weeks 16 and 52. Spirometry measurements, FeNO, and aeroallergen‐specific IgE levels during treatment were analyzed using a covariance pattern model.
Results
Eighty‐four patients were included. Asthma was diagnosed in 50 patients (59.5%) and AR in 72 patients (85.7%). Baseline FeNO levels were elevated in both patients with (29.0 ppb (95% CI 22.0–54.0)) and without asthma (26.0 ppb (95% CI 22.0–30.0)). During treatment, FeNO levels decreased (p < .001) and FEV1 scores increased (p < .001) in patients with asthma. In patients with asthma and/or AR, all aeroallergen‐specific IgE levels decreased between 61.3% and 89.1% at 52 weeks of treatment.
Conclusion
One year of dupilumab treatment, primarily indicated for AD, resulted in a significant improvement in comorbid asthma and a profound decrease in aeroallergen‐specific IgE levels in patients with asthma and/or AR.</description><subject>Adolescent</subject><subject>Allergens</subject><subject>Allergens - immunology</subject><subject>Allergic rhinitis</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - diagnosis</subject><subject>Asthma - drug therapy</subject><subject>Asthma - epidemiology</subject><subject>Asthma - immunology</subject><subject>Atopic dermatitis</subject><subject>atopy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>children</subject><subject>Clinical outcomes</subject><subject>Comorbidity</subject><subject>Dermatitis</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatitis, Atopic - immunology</subject><subject>Dupilumab</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin E</subject><subject>Immunoglobulin E - blood</subject><subject>Immunoglobulin E - immunology</subject><subject>Male</subject><subject>Monoclonal antibodies</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - metabolism</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Prevalence</subject><subject>Registries</subject><subject>Rhinitis</subject><subject>Rhinitis, Allergic - drug therapy</subject><subject>Rhinitis, Allergic - epidemiology</subject><subject>Rhinitis, Allergic - immunology</subject><subject>Spirometry</subject><subject>Treatment Outcome</subject><subject>type 2 inflammation</subject><issn>0905-6157</issn><issn>1399-3038</issn><issn>1399-3038</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp10c1q3DAUBWBRWprJpIu-QBF00yycSNaMfdVd_hMINIR0ba7tq0TBtlxJpkzWefBoMpMsChWCu9DHkcRh7KsUBzKtwxHtgVzIEj6wmVRaZ0oo-MhmQotlVshlucN2Q3gUQpaqkJ_ZjgLQugCYseczY6iJ3BneTqPtph5r7gaOIT70yHFoOZJ32HXk72nggYZgo33CaJOyAx-ptRi9bThGN6bRku_TabSBj2nSEMNPfkth6mJYXxMfiB9bd4or7unehuhXe-yTwS7Ql-2cs9_nZ3cnl9n1r4urk6PrrMlLgGyBTdoAKA1BUbRyIdIn0LS6xVxJ0ELkZOoCCiG0apY1JCxLDcLUsoZczdmPTe7o3Z-JQqx6GxrqOhzITaFSohSQlykm0e__0Ec3-SG9bq1yLRalgqT2N6rxLgRPphq97dGvKimqdTVVqqZ6rSbZb9vEqe6pfZdvXSRwuAF_bUer_ydVN0dXm8gXh1WZVA</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Rijst, Lisa P. van der</creator><creator>Groot, Karin M. de Winter‐de</creator><creator>Zuithoff, Nicolaas P. A.</creator><creator>Bruin‐Weller, Marjolein S.</creator><creator>Graaf, Marlies</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5865-8986</orcidid></search><sort><creationdate>202406</creationdate><title>Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry</title><author>Rijst, Lisa P. van der ; Groot, Karin M. de Winter‐de ; Zuithoff, Nicolaas P. A. ; Bruin‐Weller, Marjolein S. ; Graaf, Marlies</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2788-4ac4ac88a1fe866d140968afd9da23189002efb6860093c5b8c8817980fb1b823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Allergens</topic><topic>Allergens - immunology</topic><topic>Allergic rhinitis</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - diagnosis</topic><topic>Asthma - drug therapy</topic><topic>Asthma - epidemiology</topic><topic>Asthma - immunology</topic><topic>Atopic dermatitis</topic><topic>atopy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>children</topic><topic>Clinical outcomes</topic><topic>Comorbidity</topic><topic>Dermatitis</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatitis, Atopic - immunology</topic><topic>Dupilumab</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin E</topic><topic>Immunoglobulin E - blood</topic><topic>Immunoglobulin E - immunology</topic><topic>Male</topic><topic>Monoclonal antibodies</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - metabolism</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Prevalence</topic><topic>Registries</topic><topic>Rhinitis</topic><topic>Rhinitis, Allergic - drug therapy</topic><topic>Rhinitis, Allergic - epidemiology</topic><topic>Rhinitis, Allergic - immunology</topic><topic>Spirometry</topic><topic>Treatment Outcome</topic><topic>type 2 inflammation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rijst, Lisa P. van der</creatorcontrib><creatorcontrib>Groot, Karin M. de Winter‐de</creatorcontrib><creatorcontrib>Zuithoff, Nicolaas P. A.</creatorcontrib><creatorcontrib>Bruin‐Weller, Marjolein S.</creatorcontrib><creatorcontrib>Graaf, Marlies</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric allergy and immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rijst, Lisa P. van der</au><au>Groot, Karin M. de Winter‐de</au><au>Zuithoff, Nicolaas P. A.</au><au>Bruin‐Weller, Marjolein S.</au><au>Graaf, Marlies</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry</atitle><jtitle>Pediatric allergy and immunology</jtitle><addtitle>Pediatr Allergy Immunol</addtitle><date>2024-06</date><risdate>2024</risdate><volume>35</volume><issue>6</issue><spage>e14178</spage><epage>n/a</epage><pages>e14178-n/a</pages><issn>0905-6157</issn><issn>1399-3038</issn><eissn>1399-3038</eissn><abstract>Background
Atopic dermatitis (AD) is frequently associated with asthma and allergic rhinitis (AR). Dupilumab is an effective treatment for pediatric AD, although the effect on atopic comorbidities in pediatric AD patients is limited.
Objective
To investigate the prevalence of asthma and AR in pediatric AD patients starting dupilumab treatment and to evaluate the effect of dupilumab on these comorbidities.
Methods
This study included pediatric AD patients (aged 3–17 years) treated with dupilumab between 2019 and 2023. Patients were screened at baseline by a pulmonologist for the presence of asthma and AR. Screening included evaluation of medical history and current symptoms, spirometry (including Forced Expiratory Volume in 1 s (FEV1)), Fractional exhaled Nitric Oxide (FeNO), and measurement of aeroallergen‐specific IgE levels. In patients diagnosed with comorbid asthma and/or AR, measurements were repeated at weeks 16 and 52. Spirometry measurements, FeNO, and aeroallergen‐specific IgE levels during treatment were analyzed using a covariance pattern model.
Results
Eighty‐four patients were included. Asthma was diagnosed in 50 patients (59.5%) and AR in 72 patients (85.7%). Baseline FeNO levels were elevated in both patients with (29.0 ppb (95% CI 22.0–54.0)) and without asthma (26.0 ppb (95% CI 22.0–30.0)). During treatment, FeNO levels decreased (p < .001) and FEV1 scores increased (p < .001) in patients with asthma. In patients with asthma and/or AR, all aeroallergen‐specific IgE levels decreased between 61.3% and 89.1% at 52 weeks of treatment.
Conclusion
One year of dupilumab treatment, primarily indicated for AD, resulted in a significant improvement in comorbid asthma and a profound decrease in aeroallergen‐specific IgE levels in patients with asthma and/or AR.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38899688</pmid><doi>10.1111/pai.14178</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-5865-8986</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0905-6157 |
| ispartof | Pediatric allergy and immunology, 2024-06, Vol.35 (6), p.e14178-n/a |
| issn | 0905-6157 1399-3038 1399-3038 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3070827002 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adolescent Allergens Allergens - immunology Allergic rhinitis Antibodies, Monoclonal, Humanized - therapeutic use Asthma Asthma - diagnosis Asthma - drug therapy Asthma - epidemiology Asthma - immunology Atopic dermatitis atopy Child Child, Preschool children Clinical outcomes Comorbidity Dermatitis Dermatitis, Atopic - drug therapy Dermatitis, Atopic - immunology Dupilumab Female Humans Immunoglobulin E Immunoglobulin E - blood Immunoglobulin E - immunology Male Monoclonal antibodies Nitric oxide Nitric Oxide - metabolism Patients Pediatrics Prevalence Registries Rhinitis Rhinitis, Allergic - drug therapy Rhinitis, Allergic - epidemiology Rhinitis, Allergic - immunology Spirometry Treatment Outcome type 2 inflammation |
| title | Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T10%3A51%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20dupilumab%20on%20asthma%20and%20aeroallergen%20sensitization%20in%20pediatric%20atopic%20dermatitis%20patients:%20Results%20of%20the%20BioDay%20registry&rft.jtitle=Pediatric%20allergy%20and%20immunology&rft.au=Rijst,%20Lisa%20P.%20van%20der&rft.date=2024-06&rft.volume=35&rft.issue=6&rft.spage=e14178&rft.epage=n/a&rft.pages=e14178-n/a&rft.issn=0905-6157&rft.eissn=1399-3038&rft_id=info:doi/10.1111/pai.14178&rft_dat=%3Cproquest_cross%3E3070827002%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3072904738&rft_id=info:pmid/38899688&rfr_iscdi=true |